株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

多発性骨髄腫治療薬のアジア太平洋地域市場 〜2021年

Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments

発行 GBI Research 商品コード 345476
出版日 ページ情報 英文 117 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GBI Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
多発性骨髄腫治療薬のアジア太平洋地域市場 〜2021年 Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments
出版日: 2015年10月01日 ページ情報: 英文 117 Pages
概要

多発性骨髄腫は骨髄の形質細胞の増殖を特徴とする悪性血液疾患です。病態生理学の理解が進んだことから過去10年で大きな改善がみられたもののこの疾患は治療不可能なものです。現在、癌の全症例の0.8〜1%、血液癌のおよそ10%が多発性骨髄腫であり、10万人に0.4〜0.5人の発症率となっています。

当レポートでは、アジア太平洋地域における多発性骨髄腫治療薬市場について調査し、多発性骨髄腫の概要と治療法、治験とパイプライン動向、2021年までの地域別予測をまとめています。

第1章 目次

第2章 イントロダクション

  • 疾患のイントロダクション
  • 病因
  • 病態生理学
  • 症状
  • 診断と分類
  • 疫学
  • 予後と病期
  • 治療法

第3章 上市済み製品

  • 概要
  • 免疫調整剤
  • プロテアソーム阻害剤
  • ヒストンデアセチラーゼ阻害剤
  • 化学療法
  • 効能および安全性比較

第4章 パイプライン製品

  • 全体的パイプライン
  • 分子標的別パイプライン分析

第5章 治験

  • 失敗率
  • 被験者募集と治験規模
  • 期間
  • 比較治験指標分析
  • パイプラインにおける有望薬剤候補
  • パイプライン製品のヒートマップ

第6章 2021年までの市場予測

  • 地位別市場
  • アジア太平洋地域市場
  • インド
  • 中国
  • オーストラリア
  • 日本

第7章 市場促進因子と障壁

第8章 取引と戦略的連携

  • ライセンシング
  • 共同開発

第9章 付録

目次
Product Code: GBIHC370MR

Executive Summary

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8-1% of all cancer cases worldwide and approximately 10% of all hematological cancers, with incidence rates ranging from 0.4 to 5 per 100,000 persons in different parts of the world.

Without any treatment, the median survival of a myeloma patient is about six months, but this can be extended with the use of various forms of treatment. There are now five classes of drugs used in the treatment of myeloma: immunomodulatory drugs, chemotherapy, proteasome drugs, Histone Deacetylase (HDAC) inhibitors and steroids. Many of the notable drugs in these classes were approved over the past 10-15 years. Treatment using these novel drugs and high-dose chemotherapy with hematopoietic Stem-Cell Transplant (SCT) has been shown to improve median survival to five years, which makes this the current standard therapy. However, many patients suffer relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival.

Scope

The different segments of patients with MM are based on their eligibility for an SCT

  • What combination therapies are used for various segments?
  • What are the treatment options available for myeloma, providing an overview of the front-line, second-line and third-line therapies available?

There are seven main marketed products for MM, with most of the novel drugs being approved in the last decade.

  • What are the dominant mechanisms of action across marketed products?
  • Which products are approved currently in each country and which ones are likely to be launched within the forecast period?
  • Which product is used more in each country?
  • Will there be any label expansions of existing market leaders in any of the countries?

Epidemiology of MM is significantly different in Asia-Pacific countries from that in the major markets.

  • What are the various epidemiology trends in each country?
  • What factors contribute to the overall epidemiology?

The MM pipeline consists of more than 250 products in active development. Small molecules are the most abundant molecule type in the pipeline, accounting for 48% of all products.

  • What are the various pipeline products based on molecule type, mechanism of action and stage of development?
  • Which class is most prominent within the pipeline?

Do the pipeline molecules offer an advantage over commercially proven mechanisms?

  • What are the late-pipeline products expected to be launched in each country in the near future?

Analysis of clinical trials since 2006 identified that MM products have a high rate of attrition.

  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
  • What are the current promising pipeline drugs and their efficacy data?

Over the 2014-2020 forecast period, the MM market in Australia, China, India and Japan is expected to increase in value at a CAGR of 7.4%, from $1.7 billion to about $2.8 billion.

  • Which markets make the most significant contribution to the current market size?
  • What are the incidence, diagnosis and treatment trends in these markets?
  • What are the factors responsible for difference in the treatment patterns within the four markets?
  • Which factors will influence growth rates?
  • Will new market entrants lead to substantial changes in annual therapy costs?

Some key marketed products are expected to expire in the forecast period, and promising pipeline molecules are likely to be launched in the near future.

  • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
  • Will the patent expiration be offset by the approval of new therapies?

Reasons to buy

This report will enable you to -

  • Understand the clinical context of MM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Appreciate key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia and Japan.
  • Discover trends in licensing and co-development deals concerning MM products and identify the major strategic consolidations that have shaped the commercial landscape.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Etiology
  • 2.3. Pathophysiology
  • 2.4. Symptoms
  • 2.5. Diagnosis and Classification
  • 2.6. Epidemiology
  • 2.7. Prognosis and Disease Staging
  • 2.8. Treatment Options
    • 2.8.1. Treatment Algorithm
    • 2.8.2. Initial Therapy for Newly Diagnosed Symptomatic Disease
    • 2.8.3. Maintenance Therapy
    • 2.8.4. Therapy for Relapsed or Refractory Myeloma

3. Marketed Products

  • 3.1. Overview
  • 3.2. Immunomodulatory Agents
    • 3.2.1. Thalomid (thalidomide) - Celgene
    • 3.2.2. Revlimid (lenalidomide) - Celgene
    • 3.2.3. Pomalyst (pomalidomide) - Celgene
  • 3.3. Proteasome Inhibitors
    • 3.3.1. Velcade (bortezomib) - Millennium Pharmaceuticals/Takeda
    • 3.3.2. Kyprolis (carfilzomib) - Onyx
  • 3.4. Histone Deacetylase Inhibitors
    • 3.4.1. Farydak (panobinostat) - Novartis
  • 3.5. Chemotherapy
    • 3.5.1. Doxil (doxorubicin HCl liposome injection) - Janssen
  • 3.6. Comparative Efficacy and Safety of Marketed Products

4. Pipeline Products

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecular Target

5. Clinical Trials

  • 5.1. Failure Rate
  • 5.2. Patient Enrolment and Clinical Trial Size
  • 5.3. Duration
  • 5.4. Competitive Clinical Trials Metrics Analysis
  • 5.5. Promising Drug Candidates in the Pipeline
    • 5.5.1. Daratumumab - Johnson & Johnson
    • 5.5.2. Elotuzumab - AbbVie and Bristol Myers Squibb
    • 5.5.3. Ixazomib - Millennium Pharmaceuticals
    • 5.5.4. Zolinza (vorinostat) - Merck
    • 5.5.5. ARRY-520(filanesib) - Array Biopharma
    • 5.5.6. Aplidin (plitidepsin) - PharmaMar
  • 5.6. Heat Map for Pipeline Products

6. Market Forecast to 2021

  • 6.1. Geographical Markets
  • 6.2. Asia-Pacific Market
  • 6.3. India
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. China
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Australia
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size
  • 6.6. Japan
    • 6.6.1. Treatment Usage Patterns
    • 6.6.2. Annual Cost of Therapy
    • 6.6.3. Market Size

7. Drivers and Barriers for the Disease Market

  • 7.1. Drivers
    • 7.1.1. Rising Prevalence
    • 7.1.2. Increasing Therapeutic Options
    • 7.1.3. Limited Generic Competition
  • 7.2. Barriers
    • 7.2.1. Limited Target Patient Population
    • 7.2.2. Large Undiagnosed Pool
    • 7.2.3. Lower Usage of Costlier Therapies in India and China
    • 7.2.4. Costly Drug Development

8. Deals and Strategic Consolidations

  • 8.1. Licensing Deals
    • 8.1.1. PharmaMar Announces Licensing Agreement with TTY Biopharm for Aplidin in Hematological Cancers
    • 8.1.2. Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab
    • 8.1.3. Genentech Enters into Licensing Agreement with Seattle Genetics - Now Terminated
    • 8.1.4. OncoPep Enters into Licensing Agreement with Dana-Farber Cancer Institute for Cancer Vaccine Technology
    • 8.1.5. PharmaMar Enters into Licensing Agreement with Chugai for Aplidin
    • 8.1.6. Onyx Enters into Licensing Agreement with Ono Pharma for Kyprolis and Oprozomib
  • 8.2. Co-development Deals
    • 8.2.1. Celgene Enters into Co-development Agreement with MedImmune
    • 8.2.2. Acetylon Enters into Co-development Agreement with Leukemia & Lymphoma Society
    • 8.2.3. Boehringer Ingelheim Enters into Collaboration Agreement with Micromet
    • 8.2.4. Multiple Myeloma Research Foundation Enters into Co-development Agreement with Onyx
    • 8.2.5. Dana-Farber Cancer Institute Enters into Agreement with MannKind
    • 8.2.6. Nordic Nanovector Enters into Co-development Agreement with Affibody

9. Appendix

  • 9.1. All Pipeline Drugs by Phase of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. Investigational New Drug/Clinical Trial Application-Filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-registration
  • 9.2. Market Forecasts to 2021
    • 9.2.1. Asia-Pacific
    • 9.2.2. India
    • 9.2.3. China
    • 9.2.4. Australia
    • 9.2.5. Japan
  • 9.3. Bibliography
  • 9.4. Research Methodology
    • 9.4.1. Secondary Research
    • 9.4.2. Marketed Product Profiles
    • 9.4.3. Late-Stage Pipeline Candidates
    • 9.4.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.4.5. Forecasting Model
    • 9.4.6. Deals Data Analysis
  • 9.5. Expert Panel Validation
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Multiple Myeloma Therapeutics Market, Initial Screening in Suspected Myeloma Patients
  • Table 2: Multiple Myeloma Therapeutics Market, Diagnostic Criteria for MGUS, Asymptomatic Myeloma and Symptomatic Myeloma
  • Table 3: Multiple Myeloma Therapeutics Market, Myeloma-Related Organ or Tissue Impairment
  • Table 4: Multiple Myeloma Therapeutics Market, Disease Staging, Durie-Salmon Staging System
  • Table 5: Multiple Myeloma Therapeutics Market, Prognostic Factors
  • Table 6: Multiple Myeloma Therapeutics Market, Prognostic Factors
  • Table 7: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Discovery, 2015
  • Table 8: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Preclinical, 2015
  • Table 9: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2015
  • Table 10: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase I, 2015
  • Table 11: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase II, 2015
  • Table 12: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase III, 2015
  • Table 13: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Pre-registration, 2015
  • Table 14: Multiple Myeloma Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021
  • Table 15: Multiple Myeloma Therapeutics Market, India, Market Forecast, 2014-2021
  • Table 16: Multiple Myeloma Therapeutics Market, China, Market Forecast, 2014-2021
  • Table 17: Multiple Myeloma Therapeutics Market, Australia, Market Forecast, 2014-2021
  • Table 18: Multiple Myeloma Therapeutics Market, Japan, Market Forecast, 2014-2021

List of Figures

  • Figure 1: Multiple Myeloma Therapeutics Market, Australia, Age-Specific Incidence Rate and Average Number of Cases, 2007-2011
  • Figure 2: Multiple Myeloma Therapeutics Market, Treatment Algorithm for Myeloma
  • Figure 3: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment - Efficacy
  • Figure 4: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment - Safety
  • Figure 5: Multiple Myeloma Therapeutics Market, Global, Heat Map for Maintenance Treatment
  • Figure 6: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma - Efficacy
  • Figure 7: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma - Safety
  • Figure 8: Multiple Myeloma Therapeutics Market, Global, Overview of Pipeline Products
  • Figure 9: Multiple Myeloma Therapeutics Market, Global, Target Families in Pipeline
  • Figure 10: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase (%), 2006-2015
  • Figure 11: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase and Molecule Type (%), 2006-2015
  • Figure 12: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Attrition Rate and Failure Rate by Phase and Molecular Target (%), 2006-2015
  • Figure 13: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2015
  • Figure 14: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-2015
  • Figure 15: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2015
  • Figure 16: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006-2015
  • Figure 17: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2015
  • Figure 18: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2015
  • Figure 19: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 20: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Figure 21: Multiple Myeloma Therapeutics Market, Global, Pipeline Heat Map, 2015
  • Figure 22: Multiple Myeloma Therapeutics Market, Asia-Pacific, Treatment Patterns ('000) and Market Size ($bn), 2014-2021
  • Figure 23: Multiple Myeloma Therapeutics Market, India, Treatment Patterns ('000), 2014-2021
  • Figure 24: Multiple Myeloma Therapeutics Market, India, Annual Cost of Therapy ($), 2014-2021
  • Figure 25: Multiple Myeloma Therapeutics Market, India, Market Size ($m), 2014-2021
  • Figure 26: Multiple Myeloma Therapeutics Market, China, Treatment Patterns ('000), 2014-2021
  • Figure 27: Multiple Myeloma Therapeutics Market, China, Annual Cost of Therapy ($), 2014-2021
  • Figure 28: Multiple Myeloma Therapeutics Market, China, Market Size ($m), 2014-2021
  • Figure 29: Multiple Myeloma Market, Australia, Treatment Usage Patterns ('000), 2014-2021
  • Figure 30: Multiple Myeloma Market, Australia, Annual Cost of Therapy ($), 2014-2021
  • Figure 31: Multiple Myeloma Therapeutics Market, Australia, Market Size ($m), 2014-2021
  • Figure 32: Multiple Myeloma Market, Japan, Treatment Usage Patterns ('000), 2014-2021
  • Figure 33: Multiple Myeloma Market, Japan, Annual Cost of Therapy ($), 2014-2021
  • Figure 34: Multiple Myeloma Therapeutics Market, Japan, Market Size ($m), 2014-2021
  • Figure 35: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Region, 2006-2015
  • Figure 36: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Deal Value ($m), 2006-2015
  • Figure 37: Multiple Myeloma Therapeutics Market, Global, Number of Deals and Aggregate Deal Value ($m), 2006-2015
  • Figure 38: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
  • Figure 39: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015
  • Figure 40: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecular Target, 2006-2015
  • Figure 41: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Region, 2006-2015
  • Figure 42: Multiple Myeloma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, 2006-2015
  • Figure 43: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2015
  • Figure 44: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006-2015
  • Figure 45: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2015
Back to Top